Role of gamma knife radiosurgery in the treatment of prolactinomas
- 36 Downloads
Stereotactic radiosurgery is one of the treatment options for prolactinomas, the most commonly used being Gamma Knife Radiosurgery (GKRS). GKRS is indicated mainly in the treatment of dopamine agonist (DA)-resistant prolactinomas. In our study, we report on our experience in treating prolactinoma patients by GKRS.
Twenty-eight patients were followed-up after GKRS for 26–195 months (median 140 months). Prior to GKRS, patients were treated with DAs and 9 of them (32.1%) underwent previous neurosurgery. Cavernous sinus invasion was present in 16 (57.1%) patients. Indications for GKRS were (i) resistance to DA treatment (17 patients), (ii) drug intolerance (5 patients), or (iii) attempts to reduce the dosage and/or shorten the length of DA treatment (6 patients).
After GKRS, normoprolactinaemia was achieved in 82.1% of patients, out of which hormonal remission (normoprolactinaemia after discontinuation of DAs) was achieved in 13 (46.4%), and hormonal control (normoprolactinaemia while taking DAs) in 10 (35.7%) patients. GKRS arrested adenoma growth or decreased adenoma size in all cases. Two patients (8.3%) developed hypopituitarism after GKRS. Prolactinoma cystic transformation with expansive behaviour, manifested by bilateral hemianopsia, was observed in one patient.
GKRS represents an effective treatment option, particularly for DA-resistant prolactinomas. Normoprolactinaemia was achieved in the majority of patients, either after discontinuation of, or while continuing to take, DAs. Tumour growth was arrested in all cases. The risk of the development of hypopituitarism can be limited if the safe dose to the pituitary and infundibulum is maintained.
KeywordsGamma knife radiosurgery Prolactinoma Resistance Hypopituitarism
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
- 7.Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256–5261CrossRefGoogle Scholar
- 9.Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Cjanson P, Vilar L, Borson-Chazot F, Naves L, Brue T, Gatta B, Delemer B, Ciccareli E, Beck-Peccoz P, Caron P, Daly A, Beckers A (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167:651–662CrossRefGoogle Scholar
- 21.Novotný J Jr, Novotný J, Vymazal J, Liščák R, Vladyka V (1998) Assessment pf the accuracy of stereotactic target localization using magnetic resonance imaging: phantom study. J Neurosurg 1:99–111Google Scholar
- 22.Ježková J, Marek J, Liščák R (2013) Pituitary adenomas. In: Liščák R (ed) Gamma knife radiosurgery. Nova Science, New York, pp 169–188Google Scholar
- 39.Webster J, Piscitelli G, Polli A, Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, Hermite M, Ciccarelli E, European Multicenter.: Cabergoline Dose-finding Study Group (1992) Dose depend suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicenter Cabergoline Dose-findng Study Group. Clin Endocrinol 37:534–541CrossRefGoogle Scholar